Boundless Bio Inc. (BOLD)
NASDAQ: BOLDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BOLD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $54.78M
- EPS (TTM)
- -$2.46
- Dividend yield
- None
- 52-week range
- 0.961 – 3.16
- Day range
- 2.28 – 2.39
- Volume / Avg
- 147.87K / 131.34K
- Beta
- —
- Shares outstanding
- 23.61M
52-week range
BOLD stock today
On Nov 20, BOLD ended the session at $2.32, shedding $0.06 (2.52%), versus the S&P 500's 3.70% decline. Shares are 26.7% below their 52-week high of $3.16, set on Aug 24, 2026 and 141.4% above the 52-week low of $0.961, in the middle of the past year's range. BOLD is up 93.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 105.3%.
Boundless Bio has posted a net loss over the last twelve months (EPS of -$2.46), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Boundless Bio
Company profileBoundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Headquarters
- San Diego, CA
- Employees
- 28
- IPO year
- 2024
- Website
- boundlessbio.com
Financial highlights
Full financialsBoundless Bio reported a net loss of $58.2 million, compared with a loss of $65.4 million a year earlier. Diluted earnings per share came in at -$2.60.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Growth | — | — | — |
| Net income | $-58.20M | $-65.36M | $-49.43M |
| EPS (diluted) | $-2.60 | $-3.85 | $-40.65 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$4.00+72.41%
- Strong buy 0
- Buy 0
- Hold 1
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.23 vs —
BOLD news
All BOLD news- 21shares Releases Annual Outlook: 10 Predictions for Digital Assets in 2027GlobeNewswireABTC, BOLD, LINK, HODL
- Wednesday 10/21 Insider Buying Report: BOLD, OWLSNasdaqBOLD, OWLS
- 21shares Expands Digital Asset Lineup with Launch of Lighter ETP (LIHT) and Venice Token ETP (VENC)GlobeNewswireABTC, BOLD, LINK, HODL
- 21shares Launches Europe’s First Pre-IPO Synthetic Anthropic ETPGlobeNewswireABTC, BOLD, LINK, HODL
- Biotech Stocks At 52-Week Highs - ELOX, PRLD, ARGX, BOLD, CORTNasdaqARGX, BOLD, CORT, ELOX
Boundless Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AZRAzora Therapeutics Inc. | 3.85 | -0.52% | $55.00M | vs BOLD |
| XLOXilio Therapeutics Inc. | 7.56 | -1.11% | $53.40M | vs BOLD |
| KZIAKazia Therapeutics Limited ADR | 4.92 | -8.38% | $56.22M | vs BOLD |
| CTORCitius Oncology Inc. | 0.5035 | -10.95% | $53.25M | vs BOLD |
| IBIOiBio Inc. | 0.8001 | -0.11% | $56.37M | vs BOLD |
| XBITXBiotech Inc. | 1.73 | +2.98% | $52.74M | vs BOLD |
| TENXTenax Therapeutics Inc. | 1.25 | -10.07% | $56.92M | vs BOLD |
| LFVNLifevantage Corporation | 4.15 | -15.13% | $52.63M | vs BOLD |
Indexes, lists and sector
Boundless Bio stock FAQ
What is Boundless Bio's stock price today?
BOLD last traded at $2.32 as of Nov 20, 4:00 PM EST, down 2.52% on the day. Prices are delayed at least 15 minutes.
What is the BOLD 52-week high?
The 52-week high for BOLD is $3.16 and the 52-week low is $0.961. The stock is currently 26.7% below its high.